(MENAFN- EIN Presswire) EINPresswire/ -- What Is The Expected Cagr For The Fibrate Drugs Market Through 2025?
The market size of fibrate drugs has experienced a consistent increase over the past years. The value is projected to rise from $3.49 billion in 2024 to $3.58 billion in 2025, with a compound annual growth rate (CAGR) of 2.8%. The historic growth is due to the emergence of lipid control, emphasis on cholesterol management, clinical investigations and trials, along with efforts towards reducing cardiovascular risks and combined treatment methods.

In the forthcoming years, the market size of fibrate drugs is predicted to experience notable growth, eventually reaching $4.72 billion in 2029 with an annual growth rate of 7.2%. This predicted increase in the forecast duration is significantly influenced by progressive treatment protocols, efforts towards residual risk reduction, advancement in precision medicine, and innovation in drug delivery systems. Furthermore, the forecast period will be characterized by alternative drug formulations, integration of telemedicine, application of fibrates in high-risk demographics, triglyceride level targeting, and concentrated efforts towards increase in HDL.

Download a free sample of the fibrate drugs market report:

What Are The Key Factors Driving Growth In The Fibrate Drugs Market?
The escalating prevalence of cardiac ailments is anticipated to boost the growth of the fibrate drug market in the future. Cardiac diseases comprise an array of conditions that impact the heart and the blood vessels. These encompass coronary heart disease, congenital heart disease, and more. Fibrates serve as a preventive treatment for additional heart attacks and strokes in individuals who are already diagnosed with circulatory system disorders, hence catalyzing the fibrate drug market. For example, the Singapore Heart Foundation (SHF), a non-profit organization based in Singapore, reported in May 2024 that ischemic heart diseases led to 5,302 fatalities, a minor hike from 5,290 deaths in 2022. Moreover, the total death toll from hypertensive diseases noted a rise to 3.7% in 2022, from 3.4% in 2021. Consequently, the heightened prevalence of cardiac diseases is stimulating the growth of the fibrate drugs market.

What Are The Top Players Operating In The Fibrate Drugs Market?
Major players in the Fibrate Drugs include:

. Pfizer Inc.
. F. Hoffmann-La Roche AG
. Merck & Co Inc.
. AbbVie Inc.
. Bayer AG
. Novartis AG
. Sanofi SA
. Kowa Company Ltd.
. Bristol-Myers Squibb Co
. Abbott Laboratories

What Are The Major Trends That Will Shape The Fibrate Drugs Market In The Future?
To maintain their dominance in the fibrate drugs market, leading companies are focusing on creating novel solutions, such as fixed-dose combinations. A fixed-dose combination is a pharmaceutical development that contains two or more active components in a single dose, which facilitates administration and potentially enhances therapeutic results. For example, in May 2023, Intercept Pharmaceuticals Inc., a biopharmaceutical firm based in the USA, obtained U.S. FDA approval for the orphan drug designation for the fixed-dose combination of obeticholic acid (OCA) and bezafibrate. This PPAR agonist combination is being studied as a potential treatment for people suffering from primary biliary cholangitis (PBC). In the USA, OCA, a farnesoid X receptor (FXR) agonist, is marketed as Ocaliva by Intercept for PBC therapy, whereas bezafibrate, a pan-PPAR agonist, has not received approval for any indication yet.

Comprehensive Segment-Wise Insights Into The Fibrate Drugs Market
The fibrate drugs market covered in this report is segmented –

1) By Drug Type: Clofibrate, Fenofibrates, Fenofibric Acids, Gemfibrozil, Other Drugs
2) By Indication: Hypercholesterolemia, Heart Attacks, Other Indications
3) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy
4) By End User: Hospitals, Homecare, Specialty Clinics, Other End Users

Subsegments:
1) By Clofibrate: Standard Clofibrate, Combination Products
2) By Fenofibrates: Fenofibrate Capsules, Fenofibrate Tablets, Combination Products
3) By Fenofibric Acids: Fenofibric Acid Capsules, Combination Products
4) By Gemfibrozil: Standard Gemfibrozil, Combination Products
5) By Other Drugs: Other Fibrate Formulations, Emerging Fibrate Drugs

View the full fibrate drugs market report:

Global Fibrate Drugs Market - Regional Insights
In 2024, North America dominated the fibrate drugs market. The forecasted growth trends encompass regions including Asia-Pacific, Western Europe, Eastern Europe, South America, the Middle East, and Africa as noted in the fibrate drugs market report.

Browse Through More Reports Similar to the Global Fibrate Drugs Market 2025, By The Business Research Company

Drug Delivery Devices Global Market Report 2025
report/drug-delivery-devices-global-market-report

Drugs For Immunotherapy Global Market Report 2025
report/drugs-for-immunotherapy-global-market-report

Drugs For Hormonal Replacement Therapy Global Market Report 2025
report/drugs-for-hormonal-replacement-therapy-global-market-report

Speak With Our Expert:
Saumya Sahay
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email:...
The Business Research Company -

Follow Us On:
. LinkedIn:

MENAFN24112025003118003196ID1110387766